Lana Burrell

Head of Contract Development & Manufacturing Operations, Roche Global Supply Chain

“The late Dr. Stanley Hem was and continues to be one of my greatest sources of inspiration because he was so committed to his students while always setting high expectations for us. I never wanted to let him down and have maintained that same drive for excellence throughout my career.”

Ph.D. 1998, Pharmacy, Purdue University

Career Highlights
  • Serving as Global Head of Contract Development and Manufacturing for Roche in Basel, Switzerland overseeing a team of 80 employees and a global network of more than 80 global contract/external manufacturers supplying more than 50 product families across 72 countries.
  • Serving as Therapeutic Head at Janssen for a $16 billion product portfolio in Beerse,Belgium – responsible for portfolio optimization strategies for molecule medicines.
  • As Head of Cell Therapy Business Operations for Celgene, leading the establishment of a centralized cell therapy organization to advance early- and late-stage portfolios following the acquisition of Juno Therapeutics.
  • 2017 Tribute to Women in Industry (TWIN) YMCA Award – presented to women who excel in their field and made significant contributions in executive, managerial and professional roles.
  • Teaching biochemistry, microbiology, and biological manufacturing to graduate students as an Adjunct Professor of Biotechnology at the Temple University School of Pharmacy.

Lana Burrell is a results-driven global pharmaceutical supply chain leader with nearly 25 years of experience gained in the US and Europe. Lana has supported different stages of development and commercialization of life-changing biologics, small molecules, and cell therapies to radically simplify and accelerate supply to patients around the world.

In her current role as Head of Contract Development & Manufacturing Operations (CDMO) within the Roche Global Supply Chain organization, Lana leads a multinational team of more than 80 people to deliver innovative medicines to patients in 150 countries. Before relocating to Roche headquarters in Switzerland, Lana designed and built the Asset Strategy and Capital Expenditure Management Organization for Global Pharmaceutical Engineering at Genentech.

Before joining Roche/Genentech, Lana was part of the Cell Therapy Leadership Team at Celgene, where she helped develop and implement the strategy to advance early and late-stage assets.  Before joining Celgene, Lana spent 16 years at Johnson & Johnson, where she built new teams and capabilities that consistently achieved significant cost savings/avoidance, reduced risks in quality and compliance, reduced stock-outs, and increased profitability for investigational and commercially marketed medicines. Lana started her career in the industry as a Senior Scientist, first at Eisai and then at Baxter.

Lana earned a Ph.D. in Industrial and Physical Pharmacy from Purdue University and has a Six Sigma Black Belt certification. She has taught biotechnology classes to graduate pharmacy students and has published eight articles in peer-reviewed journals. Lana has received numerous employer awards for excellence in leadership and technical achievement and is passionate about improving manufacturing sustainability and increasing health equity in underserved communities.